WO2007019190A3 - Role of gax in alzheimer neurovascular dysfunction - Google Patents

Role of gax in alzheimer neurovascular dysfunction Download PDF

Info

Publication number
WO2007019190A3
WO2007019190A3 PCT/US2006/030148 US2006030148W WO2007019190A3 WO 2007019190 A3 WO2007019190 A3 WO 2007019190A3 US 2006030148 W US2006030148 W US 2006030148W WO 2007019190 A3 WO2007019190 A3 WO 2007019190A3
Authority
WO
WIPO (PCT)
Prior art keywords
gax
brain
alzheimer
gene
bec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/030148
Other languages
French (fr)
Other versions
WO2007019190A2 (en
Inventor
Berislav V Zlokovic
Zhenhua Wu
Rashid Deane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Socratech LLC
Original Assignee
University of Rochester
Socratech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester, Socratech LLC filed Critical University of Rochester
Priority to US11/988,999 priority Critical patent/US20090181911A1/en
Priority to EP06800671A priority patent/EP1909574A2/en
Publication of WO2007019190A2 publication Critical patent/WO2007019190A2/en
Publication of WO2007019190A3 publication Critical patent/WO2007019190A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Neurovascular disorder critically contributes to the development and pathogenesis of Alzheimer's disease (AD). Transcriptional profiling of human brain endothelial cells (BEC) defines a subset of age-independent genes significantly altered in AD including the homebox gene GAX whose expression controls vascular phenotype and is low in AD. By using viral-mediated GAX gene silencing and transfer, restoring GAX expression in AD BEC is angiogenic, transcriptionally suppresses the AFX1 forkhead transcription factor- mediated apoptosis, and increases the levels of a major amyloid β-peptide (Aβ) clearance receptor, the low density lipoprotein receptor-related protein 1 (LRP- 1) at the blood-brain barrier. In a mouse model of Alzheimer's disease, deletion of the Gax gene results in reductions in brain capillary density and the resting cerebral blood flow, loss of angiogenic brain response to hypoxia, and an impaired Aβ brain efflux caused by reduced LRP-1 levels. The link of GAX gene to AD neurovascular dysfunction provides new mechanistic and therapeutic insights into AD.
PCT/US2006/030148 2005-08-03 2006-08-03 Role of gax in alzheimer neurovascular dysfunction Ceased WO2007019190A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/988,999 US20090181911A1 (en) 2005-08-03 2006-08-03 Role of gax in alzheimer neurovascular dysfunction
EP06800671A EP1909574A2 (en) 2005-08-03 2006-08-03 Role of gax in alzheimer neurovascular dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70490305P 2005-08-03 2005-08-03
US60/704,903 2005-08-03

Publications (2)

Publication Number Publication Date
WO2007019190A2 WO2007019190A2 (en) 2007-02-15
WO2007019190A3 true WO2007019190A3 (en) 2007-09-13

Family

ID=37727880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/030148 Ceased WO2007019190A2 (en) 2005-08-03 2006-08-03 Role of gax in alzheimer neurovascular dysfunction

Country Status (3)

Country Link
US (1) US20090181911A1 (en)
EP (1) EP1909574A2 (en)
WO (1) WO2007019190A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059103A2 (en) * 2005-11-14 2007-05-24 Socratech L.L.C. Serum response factor and myocardin control alzheimer cerebral amyloid angiopathy
US8488857B2 (en) * 2007-03-06 2013-07-16 Koninklijke Philips Electronics N.V. Automated diagnosis and alignment supplemented with positron emission tomography (PET) and magnetic resonance (MR) flow estimation
CN114438193A (en) * 2022-02-24 2022-05-06 杭州惠煜医疗科技有限公司 Gene markers, detection methods and applications for the detection of Alzheimer's disease
EP4506012A4 (en) * 2022-04-01 2026-01-14 Zodiac Bio Tech Ltd USE OF EXTRACTS FROM VACCINIA VIRUS-INFLAMMATED RABBIT SKIN FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057496A2 (en) * 2001-01-18 2002-07-25 Socratech L.L.C. Gene expression profiling of endothelium in alzheimer's disease
EP1532258A4 (en) * 2002-06-11 2006-11-02 Socratech L L C TREATMENT OF VASCULAR DYSFUNCTION AND ALZHEIMER'S DISEASE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAILLARD ET AL.: "Percutaneous Delivery of the Gax gene Inhibits Vessel Stenosis in a Rabbit Model of Balloon Angioplasty", CARDIOVASCULAR RESEARCH, vol. 35, 1997, pages 536 - 346, XP000199995 *
PERLMAN ET AL.: "Adenovirus-Mediated Delivery of the Gax Transcription Factor to Rat Carotid Arterties Inhibits Smooth Muslce Proliferation and Induces Apoptosis", GENE THERAPY, vol. 6, 1999, pages 758 - 763, XP003023720 *

Also Published As

Publication number Publication date
US20090181911A1 (en) 2009-07-16
WO2007019190A2 (en) 2007-02-15
EP1909574A2 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
Lin et al. Systemic inflammation mediates age-related cognitive deficits
Greden The burden of recurrent depression: causes, consequences, and future prospects
Pariante Depression, stress and the adrenal axis
Ryan et al. Intermittent hypoxia and activation of inflammatory molecular pathways in OSAS
Bai et al. Neuropathy and presence of emotional distress and depression in longstanding diabetes: results from the Canadian study of longevity in type 1 diabetes
WO2007019190A3 (en) Role of gax in alzheimer neurovascular dysfunction
Clayton et al. Assessment of paroxetine-induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire.
Wang et al. The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient
Davis et al. Neurologic manifestations of systemic disease: Sleep disorders
Cavaliere et al. Characterization of chronic rhinosinusitis patients based on markers of type 2 inflammation: findings from the European CRS outcome registry (CHRINOSOR)
Scherer et al. Measuring Participation and the Disability Experience with the" Assistive Technology Device Predisposition Assessment"
Basaldella et al. La salute mentale in adolescenza: Sfide, opportunità e modelli di intervento
Mazzeo et al. High glucose and hypoxia-induced damage in the inner blood retinal barrier is counteracted by thiamine supplementation
Thrasher et al. A32 THE ROLE OF GUT MICROBIOTA AND TRACE AMINES IN A MURINE MODEL OF GENERALIZED ANXIETY DISORDER
Massidda et al. Physical Activity Levels And Health-related Quality Of Life In Italian University Students
Powell et al. New directions in understanding the link between stress and health in women
Maekawa et al. WCN26-6155 Low-Frequency Hearing Loss as an Independent Predictor of Frailty in Hemodialysis Patients
Cavaliere Tenrikyo
Doucette et al. Evaluating the Effect of Washington and Colorado’s Cannabis Legalization on Death by Suicide
Zimbudzi et al. A codesigned kidney and diabetes model of care improves patient activation for culturally diverse patients
TELMON Telemedicine in home hemodialysis: solutions available and their acceptability
Palmer et al. PDB33 COST-CONSEQUENCE ANALYSIS OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES INA FRENCH SETTING
Tarn et al. PDB34 DIABETES PREVALENCE AND DIRECT MEDICAL COST ANALYSIS PER YEAR FROM 1997 TO 2001 IN TAIWAN
Rubio-Terrés et al. PDB35 THE COST OF DIABETES MELLITUS IN SPAIN
Ingegnoli et al. Primary antiphospolipid syndrome associated with small aorta syndrome: a case report.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006800671

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11988999

Country of ref document: US